Moderna Inc MRNA has announced new clinical data on its omicron-containing bivalent COVID-19 booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern.
A 50 µg booster dose of mRNA-1273.214 met all pre-specified endpoints, including superior neutralizing antibody response against the omicron variant one month after administration compared to the original mRNA-1273 vaccine.
The booster dose of mRNA-1273.214 was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 µg dose level.
Binding antibody titers were also significantly higher against all other variants of concern. The mRNA-1273.214 50 μg booster dose was well-tolerated in the 437 study participants.
The safety and reactogenicity profile of the mRNA-1273.214 50 μg booster dose was similar to that of the mRNA-1273 50 μg dose when these vaccines were administered as a second booster dose.
Moderna will report data from Day 91 after vaccination later in the summer. The company plans to submit the interim analysis and data to regulators for review in the coming weeks.
Price Action: MRNA shares are down 0.23% at $145 during the premarket session on the last check Wednesday.
Photo by mufidpwt via Pixabay
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.